Programmed Death-ligand 1(PD-L1) and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced Non-small Cell Lung Cancer (NSCLC) Patients

Trial Profile

Programmed Death-ligand 1(PD-L1) and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced Non-small Cell Lung Cancer (NSCLC) Patients

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ATHENE
  • Most Recent Events

    • 15 Oct 2017 Status changed from not yet recruiting to recruiting, according to trial design presented at the 18th World Conference on Lung Cancer.
    • 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.
    • 01 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top